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Rehabilitation strategies following
oesophagogastric and
Hepatopancreaticobiliary cancer (ReStOre
II): a protocol for a randomized controlled
trial
Linda O’Neill1* , Emer Guinan2, Suzanne Doyle3, Deirdre Connolly4, Jacintha O’Sullivan5, Annemarie Bennett6,
Grainne Sheill1, Ricardo Segurado7, Peter Knapp8, Ciaran Fairman9, Charles Normand10, Justin Geoghegan11,
Kevin Conlon11,12,13, John V. Reynolds5 and Juliette Hussey1
Abstract
Background: Curative treatment for upper gastrointestinal (UGI) and hepatopancreaticobiliary (HPB) cancers,
involves complex surgical resection often in combination with neoadjuvant/adjuvant chemo/chemoradiotherapy.
With advancing survival rates, there is an emergent cohort of UGI and HPB cancer survivors with physical and
nutritional deficits, resultant from both the cancer and its treatments. Therefore, rehabilitation to counteract these
impairments is required to maximise health related quality of life (HRQOL) in survivorship. The initial feasibility of a
multidisciplinary rehabilitation programme for UGI survivors was established in the Rehabilitation Strategies
following Oesophago-gastric Cancer (ReStOre) feasibility study and pilot randomised controlled trial (RCT). ReStOre II
will now further investigate the efficacy of that programme as it applies to a wider cohort of UGI and HPB cancer
survivors, namely survivors of cancer of the oesophagus, stomach, pancreas, and liver.
Methods: The ReStOre II RCT will compare a 12-week multidisciplinary rehabilitation programme of supervised and
self-managed exercise, dietary counselling, and education to standard survivorship care in a cohort of UGI and HPB
cancer survivors who are > 3-months post-oesophagectomy/ gastrectomy/ pancreaticoduodenectomy, or major
liver resection. One hundred twenty participants (60 per study arm) will be recruited to establish a mean increase in
the primary outcome (cardiorespiratory fitness) of 3.5 ml/min/kg with 90% power, 5% significance allowing for 20%
drop out. Study outcomes of physical function, body composition, nutritional status, HRQOL, and fatigue will be
measured at baseline (T0), post-intervention (T1), and 3-months follow-up (T2). At 1-year follow-up (T3), HRQOL
alone will be measured. The impact of ReStOre II on well-being will be examined qualitatively with focus groups/
interviews (T1, T2). Bio-samples will be collected from T0-T2 to establish a national UGI and HPB cancer survivorship
biobank. The cost effectiveness of ReStOre II will also be analysed.
(Continued on next page)
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Discussion: This RCT will investigate the efficacy of a 12-week multidisciplinary rehabilitation programme for
survivors of UGI and HPB cancer compared to standard survivorship care. If effective, ReStOre II will provide an
exemplar model of rehabilitation for UGI and HPB cancer survivors.
Trial registration: The study is registered with ClinicalTrials.gov, registration number: NCT03958019, date registered:
21/05/2019
Keywords: Oesophagogastric cancer, Pancreatic cancer, Liver cancer, Hepatobiliary cancer, Multidisciplinary
rehabilitation, Exercise, Diet
Background
With gradually improving survival rates, optimising the
quality of upper gastrointestinal (UGI) and hepatopan-
creaticobiliary (HPB) cancer survivorship has come to
the fore of UGI and HPB cancer research. Indeed, the
need for rehabilitative strategies to counteract the multi-
tudinous physical and nutritional side effects of UGI and
HPB cancers and their treatments has increasingly been
highlighted in the literature [1–3]. For potentially cura-
tive disease, surgical resection remains the mainstay
treatment [4–6]. However, UGI and HPB surgery is in-
herently complex, and the associated risk of mortality
and morbidity greatly exceeds that of other surgical pro-
cedures [7]. UGI and HPB resection leads to anatomical,
and physiological changes in the GI tract resulting in
significant issues with malnutrition and malabsorption
post-operatively [8]. Furthermore, for locally advanced
UGI and HPB cancers, a multimodality treatment ap-
proach, which combines surgery with neoadjuvant/adju-
vant chemo/chemoradiotherapy, is favoured for its
significant survival advantages compared to surgery
alone [9, 10]. However, these treatments may precipitate
further decrements in nutritional status [11]. Conse-
quently, persistent weight loss and sarcopenia are ubi-
quitous in UGI and HPB cancer survivorship [3, 12], and
in parallel there are prevailing impairments in physical
function and health related quality of life (HRQOL) [1,
13–15]. Therefore, rehabilitative strategies that aim to
minimize physical and nutritional deficits and in turn
improve the health and well-being of survivors require
exploration in this cohort.
Given the combined physical and nutritional chal-
lenges of UGI and HPB cancer survivorship, lifestyle in-
terventions such as exercise and/or dietary rehabilitation
are potential cost-effective strategies. Increasingly exer-
cise interventions are advocated due to their positive ef-
fects on physical function, muscle strength, psychosocial
status, and HRQOL [16, 17], and dietary programmes
for their association with improvements in body weight
and diet quality [18]. Therefore the potential benefits of
such rehabilitative measures in UGI and HPB survivor-
ship should not be underestimated. Moreover, increas-
ingly UGI and HPB cancer survivors are reporting their
need for, and willingness to engage in rehabilitation [19].
However, evidence supporting rehabilitation strategies in
UGI and HPB cancer is currently lacking [2].
Preliminary work at this centre has established the
safety, feasibility and initial efficacy of multidisciplinary
rehabilitation in oesophago-gastric cancer survivorship
[20–22]. The ReStOre (Rehabilitation Strategies follow-
ing Oesophago-gastric Cancer) feasibility study and pilot
RCT demonstrated that a 12-week programme of super-
vised and homebased exercise, 1:1 dietary counselling,
and health education could result in clinically significant
improvements in cardiorespiratory fitness [21, 22], and
physical and mental well-being [23] without compromise
to body composition. Thus the ReStOre RCT is the first
evidence-based model of rehabilitation in UGI cancer
survivorship. The ReStOre II RCT will now further
examine the effectiveness of the ReStOre programme by
RCT in a larger cohort of UGI and HPB cancer
survivors.
Methods
Study aims
The primary aim of this work is to examine if a multidis-
ciplinary cancer rehabilitation programme (ReStOre II),
incorporating exercise and diet prescription, designed and
tailored for disease-free survivors of UGI and HPB can-
cers, namely cancer of the oesophagus, stomach, pancreas
and liver, can lead to improvements in cardiorespiratory
fitness in comparison to standard survivorship care.
Secondary aims are;
 To examine the effect of the ReStOre II programme
on physical functioning
 To determine the impact of the ReStOre II
programme on body composition
 To explore the effect of the ReStOre II programme
on dietary quality and nutritional status
 To examine the early and longer-term effects of the
ReStOre II programme on patient reported out-
comes including HRQOL, and fatigue
 To qualitatively examine the effects of the ReStOre
II programme on physical, mental, and social well-
being
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 To evaluate the cost effectiveness of the ReStOre II
programme
 To establish an UGI cancer survivorship biobank for
collaborative translational research studies.
Study design
Using a convergent parallel mixed-methods study de-
sign, ReStOre II will be carried out as a randomised con-
trolled trial with two arms: i) an intervention group
offered the 12 week ReStOre II programme in addition
to usual care, and ii) a control group receiving usual
care. The flow of participants through the study is pre-
sented in Fig. 1. The study will recruit participants from
three large teaching hospitals in Dublin, Ireland (St
James’s Hospital, St Vincent’s University Hospital, and
Tallaght University Hospital). Ethical approval has been
granted from their respective research ethics committees
and any subsequent amendments to the trial protocol
will be submitted for their approval. The study will be
conducted in accordance with the Declaration of
Helsinki.
Study participants
ReStOre II will recruit 120 patients with a histological
confirmed diagnosis of cancer of the oesophagus, stom-
ach, pancreas, or liver who have undergone surgery with
curative intent. Participants must meet the following eli-
gibility criteria; be ≥ three months post oesophagectomy,
total gastrectomy, pancreaticoduodenectomy, or major
liver resection, ± neo-adjuvant/adjuvant chemo/chemo-
radiotherapy with curative intent, and adjuvant therapy
must be completed. Exclusion criteria are; ongoing ser-
ious post-operative morbidity, and, evidence of active or
recurrent disease. In addition, those with any serious co-
morbidity that would impact on exercise participation
will be excluded, including those with; electrocardio-
graph (ECG) abnormalities at rest or during Cardiopul-
monary Exercise Test (CPET), congestive heart failure
(NY Heart Association Class II, III or IV), uncontrolled
hypertension (resting systolic blood pressure > 180
mmHg and/or diastolic > 100mmHg), recent serious
cardiovascular events (within 12months) including, but
not limited to, cerebrovascular accident, and myocardial
infarction, unstable cardiac, renal, lung, liver or other se-
vere chronic disease, uncontrolled atrial fibrillation, or
left ventricular function < 50%, %; and, severe/ very se-
vere chronic obstructive disease (COPD) (GOLD Stages
III/IV FEV1 < 50%, FEV1/FVC < 70%).
Recruitment and screening
Members of the clinical team will determine potential
participants from post-operative clinic lists and from
hospital databases. Eligibility screening will be then be
processed by the research team and research nurses.
Written medical clearance from each participant’s treat-
ing consultant will be a pre-requisite to trial enrolment.
Potential participants will receive a participant informa-
tion leaflet (PIL) from a member of the study team. Fol-
lowing receipt of the trial PIL potential participants will
then be given a one-week reflection period to consider
their interest in trial participation. Upon completion of
the reflection window, patients will receive a telephone
call to establish whether they wish to participate. Those
who express an interest in participation will be asked to
attend a screening assessment in which they will provide
written informed consent and complete baseline mea-
sures. This baseline assessment will take place in the
Clinical Research Facility (CRF) at St James’s Hospital
(SJH). If accrual is lower than anticipated, recruitment
may also be expanded by advertising the study through
charity partners; the Irish Cancer Society and the
Oesophageal Cancer Fund.
Randomisation and blinding
Following successful completion of baseline assess-
ments, including a CPET, participants will be formally
Fig. 1 Participant flow through study
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registered on the trial and will be randomised to the
ReStOre II programme or the usual care control
group. Block randomisation will be performed using a
computer-generated randomisation list. Randomisation
will be administered independently by the CRF at
SJH. Study assessments will be performed by an as-
sessor concealed to allocation. Given the design of
the ReStOre II programme, it will not be feasible to
blind either the research staff responsible for deliver-
ing the ReStOre intervention or trial participants to
their allocation.
Intervention
The ReStOre II intervention will take place in the exer-
cise physiology suite at the CRF at SJH. The programme
will follow a modified version of our established protocol
from the ReStOre I study [22]. The ReStOre II
programme comprises three elements: supervised and
home-based exercise training, individualised dietetic
counselling, and multidisciplinary education. The inter-
vention is summarised in Table 1. In line with the Irish
National Cancer Strategy 2017–2026 [24], key to the de-
livery of the programme will be an emphasis on self-
management. At the start of the programme participants
will set personal goals for the programme. Furthermore,
each week participants will also set a specific personal
goal for the coming week.
Exercise
The exercise component will consist of a 12-week super-
vised and home-based intervention. The exercise pre-
scription will include both aerobic and resistance
training and will be prescribed by a physiotherapist. Su-
pervised group exercise sessions will be held twice
weekly during the first 4 weeks to reintroduce exercise
to participants in a safe and structured manner. As the
programme progresses the frequency of supervised ses-
sions will decrease, and the frequency of home-based ex-
ercise sessions will increase. This structure aims to
encourage self-management in survivorship and increase
autonomy with exercise prescription.
The ReStOre II exercise prescription is presented in
Table 2. Aerobic training intensity will be individualised
to the participant’s fitness. Exercise intensity will be pre-
scribed using heart rate reserve (HRR) calculated using
the Karvonen formula (HRR =maximum heart rate –
resting heart rate) [25]. The values for maximum heart
rate and resting heart rate will be calculated during the
baseline CPET. Participants will wear Polar Heart Rate
monitors to ensure compliance with the prescribed exer-
cise intensity. Intensity will also be monitored with the
Borg Perceived Scale of Exertion [26]. Upon completion
of the ReStOre II programme, participants will be com-
pleting 150 min of moderate-vigorous intensity activity
per week, as per ACSM physical activity guidelines [16].
Resistance training will also be tailored to the partici-
pant’s fitness levels. Specifically, the first week will be
used to ensure safe and appropriate technique on all ex-
ercises and determine the training loads for subsequent
sessions. The program will consist of 5 major move-
ments (squat, lunge, hip flexion/extension, pushing and
pulling) incorporating compound exercises targeting
major muscle groups of the upper and lower body. Add-
itionally, accessory movements targeting the biceps and
triceps will be incorporated. Resistance will be added
using free weights, resistance bands, a leg press machine,
or body weight. Participants will be provided with resist-
ance equipment for use at home. Where possible, load-
ing will be progressed throughout the programme using
the “2 for 2 rule” [27]. If an individual can complete two
additional repetitions of an exercise, for 2 consecutive
sessions, the weight for that exercise will be increased in
the next session. We will target weight increases of ~ 5–
10% for upper body exercises and 10–15% for lower
body exercises [27]. In exercises where load can’t be
added, participants will be asked to complete additional
sets and/or reps of each exercise to ensure progression
of training across the programme.
At each supervised session the exercise log will be
reviewed by the physiotherapist, to monitor adherence
and to facilitate exercise goal setting with the participant
for the coming week. Adherence to the home-based ex-
ercise sessions will be monitored using Polar Heart Rate
monitors and an exercise log. Adherence and compli-
ance to resistance exercise component will be calculated
using previously reported metrics [28]. Specifically, we
will track what was initially prescribed, vs. what was ac-
tually achieved for each participant. These details and
any deviations from the exercise protocol will be re-
ported in the final manuscript. This programmme was
Table 1 The ReStOre II programme
Week 1 2 3 4 5 6 7 8 9 10 11 12
Supervised exercise sessions ×2 ×2 ×2 ×1 ×1 ×1 × 1 × 1 – × 1 – × 1
Home based exercise ×1 ×1 ×2 ×2 ×3 × 3 × 3 × 3 ×5 ×4 ×5 ×4
1:1 Dietetic sessions ×1 ×1 ×1 ×1 ×1 ×1 ×1
Group education sessions ×1 ×1 × 1 × 1 ×1 ×1 ×1 ×1
Depicts frequency of sessions per week
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chosen in accordance with our exercise facilities and re-
sources available and has been utilised in prior studies
with individuals with cancer [29, 30].
Dietary counselling
One-to-one dietetic sessions will be delivered during
week 1, week 2 and fortnightly thereafter, or more fre-
quently if required. Dietetic sessions will be delivered by
a registered dietitian. Weight and circumferential mea-
sures will be recorded at each session and dietary intake
will be assessed using tailored dietary interview strategies
(incorporating 24-h recalls and qualitative information
such as meal pattern and eating strategies). Nutritional
requirements will be estimated using validated equations
combined with appropriate stress and activity factors.
The education delivered in the dietetic sessions will be
individualised to participants’ needs, considering any
dietary challenges such as dysphagia or malabsorption.
The target for participants is to optimise dietary intake,
ensuring adequate energy and micronutrient status, in
alignment with the World Cancer Research Fund
(WCRF) [31] and European Society for Clinical Nutri-
tion and Metabolism (ESPEN) [32] guidelines for cancer
survivors .
Multidisciplinary education
Education sessions (n = 7) will be delivered weekly dur-
ing weeks 1–4 and fortnightly thereafter by a range of
members of the multidisciplinary team including a doc-
tor, dietitian, occupational therapist, and physiotherapist.
Education topics will include an introduction to the Re-
StOre II programme and talks on items of pertinence to
UGI and HPB cancer survivors including; benefits of
physical activity, nutrition, management of ongoing
medical issues in survivorship, fatigue management, and
mindfulness.
Standard care group
Participants in the control group will continue to receive
standard care.
Measures
ReStOre II study outcomes are listed in Table 3. The
main assessment battery will be performed at; baseline
(T0), post-intervention (T1), and 3-months post inter-
vention (T2). Quality of life will be further assessed at 1-
year post intervention (T3). At baseline information re-
garding socio-demographics will be collected from pa-
tient interview and data pertaining to medical history,
Table 2 ReStOre II exercise prescription
Aerobic Training Resistance Training
Frequency Intensity Time Frequency Intensity Sets x
RepsSupervised
Intervention
Home Exercise
Programme
Supervised
Intervention
Home Exercise
Programme
Week 1 2 1 40–45%
HRR
20 1 0 ~16RM 1 ×
12
Week 2 2 1 40–45%
HRR
20 1 0 ~14RM 2 ×
12
Week 3 2 2 45–50%
HRR
20 2 0 ~14RM 3 ×
12
Week 4 2 2 45–50%
HRR
25 2 0 ~14RM 3 ×
12
Week 5 1 3 45–50%
HRR
25 1 1 ~12RM 3 ×
10
Week 6 1 3 50–60%
HRR
25 1 1 ~12RM 3 ×
10
Week 7 1 3 50–60%
HRR
30 1 1 ~11RM 4 ×
10
Week 8 1 3 50–60%
HRR
30 1 1 ~10RM 3 × 8
Week 9 0 4 60–75%
HRR
30 0 2 ~10RM 3 × 8
Week
10
1 4 60–75%
HRR
30 1 1 ~8RM 3 × 6
Week
11
0 5 65–80%
HRR
30 0 2 ~7RM 4 × 6
Week
12
1 4 65–80%
HRR
30 1 1 ~12RM 2 × 8
Abbreviations: HRR heart rate reserve, X1RM X-repetition maximum, Reps number of repetitions
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cancer diagnosis and treatments will be obtained from
patient’s medical records.
Primary outcome - cardiopulmonary fitness
In ReStOre II, cardiopulmonary fitness, an important
index of health [33], will be measured as the primary
outcome during a maximal CPET. The CPET will be
performed under medical supervision, using a ramp
cycle ergometer protocol with breath-by-breath analysis
(COSMED K4B2). The ramp gradient will be set to 10–
25 watts/minute based on a calculation using predicted
unloaded VO2, predicted VO2 at peak exercise, height,
and age using the following standard equations [34].
1. VO2 unloaded in millilitres/minute (ml/min) =
150 + (6 x weight (kg))
2. Peak VO2 in ml/min = (height (cm) –age (years)) ×
20(sedentary men) or × 14 (sedentary women)
3. Work rate increment minute/watts = ((peak VO2
ml/min – VO2 unloaded ml/min)/100)
Prior to test commencement, participants will under-
take a 3 min warm-up of unloaded cycling. Breath-by-
breath gas analysis, heart rate, ECG, blood pressure, oxy-
gen saturation and blood lactate will be measured be-
fore, during and after testing. Testing will be terminated
when the participant can no longer continue. Test ter-
mination will be followed by a 2 min cool down at a re-
sistance of 30 watts, during which participants will be
monitored for signs of distress. Peak oxygen uptake
(VO2peak) will be calculated as the average value over
the last 30 s of the test. Other values that will be
Table 3 ReStOre II study outcomes
Outcome Instrument Baseline Post-
intervention
3-month follow-
up
1-year follow-
up
T0 T1 T2 T3
Primary outcome
Cardiorespiratory fitness Cardiopulmonary Exercise Test (CPET) X X X
Secondary outcomes
Functional performance Short Physical Performance Battery (SPPB) X X X
Muscle Strength Leg Press 1-RM X X X
Hand grip strength (HGS) X X X
Physical activity Actigraph GT3X+ accelerometer X X X
Body composition Anthropometry X X X
Mid arm and waist circumference X X X
Bioimpedance analysis X X X
Dietary intake Dietary interview X X X
Foodbook24 X X X
Nutrition-related symptoms Gastrointestinal Symptom Rating Scale (GSRS) X X X
Simplified Nutritional Appetite Questionnaire
(SNAQ)
X X X
Quality of Life EORTC-QLQ-C30 X X X X
Cancer specific quality of
Life
EORTC-QLQ-OG25 (oesophago-gastric cancer) X X X X
EORTC-QLQ-HCC18 (liver cancer) X X X X
EORTC-QLQ-PAN26 (pancreatic cancer) X X X X
Fatigue Multidimensional Fatigue Inventory (MFI-20) X X X
Qualitative approach Semi –structured interviews (focus groups or 1:1) X X
Cost analyses Clinical salaries, overheads and equipment costs X
Blood samples Serum, plasma and whole blood X X X
Adherence Record in case report form/ exercise diary X
Other
Sociodemographic details Participant self-report X
Medical/ Cancer history Medical records X
Adverse events Reports of patients/ research personnel X X X X
O’Neill et al. BMC Cancer          (2020) 20:415 Page 6 of 12
recorded include; anaerobic threshold (lactate and venti-
lator threshold), peak work rate, peak heart rate and the
respiratory exchange ratio.
Physical functioning
Physical functioning will be examined using a suite of
validated objective measures examining functional per-
formance, muscle strength, and physical activity. Func-
tional performance will be determined using the Short
Physical Performance Battery (SPPB). The SPPB is a reli-
able measure of physical functioning which consists of a
gait speed, chair stand and balance test [35]. Scores
range from 0 to 12, wherein a higher score indicates
greater functional ability. Lower limb muscle strength
will be measured by a 1-repetition maximum (1-RM) leg
press test. The 1-RM is defined as the highest load that
can be lifted through full range of movement at one time
[36]. Participants will complete an appropriate aerobic
and low intensity warm-up at 60% 1-RM and 80% 1-RM
before a maximum of 5 trials to determine 1-RM. Hand
grip strength (HGS) will be measured by handheld dyna-
mometry. HGS provides a measure of hand and forearm
strength and is found to correlate well with overall
muscle strength and physical function [37]. For testing
the participant will be seated, elbows at 90 degrees.
Three attempts will be made on each hand with a 1-min
rest between attempts. The highest value will be re-
corded. Physical activity levels will be measured by accel-
erometry using Actigraph GT3X+ activity monitors. The
Actigraph GT3X+ is a well validated tool, used widely in
oncology [38]. The small lightweight device will be worn
at the hip for 7 days during waking hours to capture ha-
bitual physical activity. Data will be analysed with Acti-
life software using standardised algorithms to analyse
time in physical activity domains (light, moderate and
vigorous intensity) and adherence to ACSM physical ac-
tivity guidelines (150 min moderate-to-vigorous intensity
physical activity/week, accumulated in bouts ≥10min)
[36].
Body composition
Measures of body composition will include anthropom-
etry and bioimpedance analysis (BIA). Weight (kilo-
grammes (kg)) and height (centimetres (cm)) will be
recorded by standard methods as previously reported in
the ReStOre feasibility study [21] and pilot RCT [22].
Body mass index (BMI) will be calculated as weight (kg)/
height (metres (m2)). Circumferential measurements
(mid-arm muscle circumference and waist circumfer-
ence) will be performed by standard procedures [39],
taken in duplicate, and averaged for data entry. BIA will
be used to determine body composition and will be per-
formed using the SECA mBCA 515 (Seca, Hamburg,
Germany). Measures recorded will include; fat mass, fat
free mass, and skeletal muscle mass.
Dietary adequacy and nutrition related symptoms
Dietary intake and adequacy will be assessed by the
study dietitian at T0, T1, and T2 using a structured diet-
ary interview. In addition, for quantitative assessment,
participants will complete a validated digital food fre-
quency questionnaire, Foodbook24 [40]. Nutrition re-
lated symptoms will also be assessed using the validated
Gastrointestinal Symptom Rating Scale (GSRS) [41], and
the Simplified Nutritional Appetite Questionnaire
(SNAQ) [42].
Quality of life
HRQOL will be determined by the European Organisa-
tion for Research and Treatment of Cancer Quality of
Life Questionnaire (EORTC-QLQ-C30 version 3.0) and
its relevant subscales. The EORTC-QLQ-C30 consists of
functional scales (physical, role, cognitive, emotional,
and social), symptom scales (fatigue, pain, nausuea and
vomiting), global health status and HR-QOL scale, in
addition to several single item symptom measures [43].
Cancer specific QOL issues will be assessed using the
appropriate cancer subscale; QLQ-OG25 (oesophago-
gastric cancer), QLQ-HCC18 (hepatocellular cancer),
and QLQ-PAN26 (pancreatic cancer). To interpret the
core questionnaire and cancer specific subscales, higher
functional scores indicate greater functioning, whereas
lower symptom scores indicate less symptom burden.
Fatigue
Fatigue will be measured using the Multidimensional Fa-
tigue Inventory (MFI-20). The MFI-20 is a 20-item scale
that measures the impact of fatigue in five dimensions:
general, physical, cognitive, motivation and usual activ-
ities. It is scored from 0 to 20, with a cut-off score of
≥13 indicating severe fatigue. The psychometric proper-
ties of the MFI-20 have been tested and determined
strong validity and reliability [44].
Qualitative data collection
Qualitative methods will be utilised to investigate inter-
vention participants’ perceptions of the impact of the
ReStOre II programme on their daily lives. Data will be
collected through semi-structured focus group discus-
sions immediately post-intervention (T1) and individual
interviews at 3-months follow-up (T2). Focus groups at
T1 will specifically explore the impact of the ReStOre
II programme on mental, physical, and social well-being,
whilst also examining the value of the group-based exer-
cise programme and education talks to recovery. Individ-
ual interviews at T2 will focus more on examining the
maintenance of health behaviours acquired during
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participation in the ReStOre programme. Interviews and
focus groups will be led by a researcher experienced in
qualitative methods and audio-recorded followed by ver-
batim transcription in preparation for data analysis.
Cost analysis
Programme implementation costs will be analysed in
consideration of programme costs (e.g. clinician salaries,
overheads and equipment costs). Changes in HR-QOL
scores will be analysed and cost-effectiveness ratios cal-
culated. The patterns of service use and related costs will
be assessed for patients in each arm of the study, and
alongside the costs of the intervention a comparison will
be made of the total costs and outcomes, to estimated
cost-effectiveness ratios.
Biosample collection
Serum, plasma, and whole blood samples will be col-
lected at T0, T1, and T2 for the purpose of establishing
a national UGI cancer survivorship biobank. Samples
will be processed and stored at -80 °C at the Trinity
Translational Medicine Institute, St James’s Hospital,
Dublin 8 for future analyses to explore the mechanistic
pathways underpinning the impact of multidisciplinary
rehabilitation in survivorship.
Intervention Fidelity
In line with recent findings by Nilsen et al. [45], our re-
search group also recognises the need to enhance
reporting of adherence in exercise oncology trials. To
this end, whilst also reporting on traditional adherence
variables in our current research portfolio, we are now
also endeavouring to report on additional variables
adapted from drug trials in all our exercise oncology tri-
als [45]. The ReStOre II trial will report on standard var-
iables including supervised session attendance and the
completion rate of home-based exercise sessions. Akin
to our current PRE-HIIT trial examining high intensity
interval training in advance of major thoracic surgery for
cancer of the lung or oesophagus [46], ReStOre II will
also include a number of novel adherence variables
which are outlined fully in Table 4.
Safety
Patient safety will be paramount to the implementation
of the ReStOre II trial. Standard safety measures will in-
clude; written medical clearance, and successful comple-
tion of a medically supervised CPET prior to trial
commencement. All trial assessments and supervised ex-
ercise sessions will take place in the CRF which is lo-
cated within the confines of SJH and is covered by their
emergency response team. All adverse events will be
documented, and serious adverse events will be commu-
nicated to the SJH/TUH and SVUH research ethics
committees. Weight loss is a particular concern for UGI
cancer survivors, and accordingly the study dietitian will
monitor weight closely during the ReStOre II
programme.
Sample size calculation
Using data from the ReStOre pilot RCT [22] and sup-
porting published literature [47], a sample size of 96 (48
per arm) is needed to detect a mean increase of 3.5 ml/
min/kg in the intervention arm, assuming a 1.75 ml/kg/
min increase in the control arm and standard deviation
of change of 2.59 ml/kg/min for each arm, with 90%
power at the 5% significance level based on a two-
sample t-test. Given an expected attrition rate of 20%, a
sample of 120 participants (60 per arm) will be
recruited.
Data management and analysis
The Data Management Plan will outline how research
data will be handled during and after the project. Out-
come assessments will be recorded in a paper-based case
report form and then entered into a password protected
Table 4 Exercise adherence variables
Variable Definition
Total number of supervised sessions attended Total number of supervised sessions attended in the CRF at SJH
Total number of homebased sessions
completed
Total number of homebased sessions reported in exercise diary as complete
Total number of compliant aerobic sessions
completed
Total number of aerobic sessions (supervised/unsupervised) where prescribed aerobic exercise
dosage was achieved
Total number of compliant resistance sessions Total number of resistance sessions (supervised/unsupervised) where prescribed resistance training
dosage was achieved
Permanent treatment discontinuation Permanent discontinuation of the ReStOre II programme before week 12
Treatment interruption Missing at least three consecutive supervised ReStOre II sessions
Dose modification Number of supervised sessions requiring exercise dose modification
Early session termination Number of supervised sessions requiring early session termination
Pre-treatment intensity modification Number of supervised sessions requiring modification because of a pre-exercise screening indication.
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computer data repository. Data validation will be used to
avoid erroneous data entry. All participants will be allo-
cated a unique study code. The key to the study code
will be stored securely and separately. All paper records
will be stored in locked filing cabinets, in a locked office
in a restricted access building with swipe access. Elec-
tronic records will be stored on password protected
encrypted devices. Upon completion of the trial an
anonymised data set will be deposited on a secure online
repository in line with open access publication
requirements.
Quantitative data analysis will be completed using
IBM SPSS software. Baseline characteristics will be pre-
sented for each study arm. Values for normally distrib-
uted continuous variables will be presented as means
(standard deviations), whereas data which does not fol-
low a normal distribution will be presented as median
(range). Categorical variables will be displayed as counts
and proportions. A linear mixed model will be used to
model the longitudinal change in the primary response
between the groups, allowing pair-wise deletion for
missing data and allowing for within subject correlations
in the repeated measures across time. The variance-
covariance structure will be decided based on parsimony,
and the ReStOre pilot RCT data. The model will inher-
ently adjust for the baseline response variable. The pri-
mary endpoint will be the p-value for the interaction of
time-point with treatment arm. The primary analysis set
will comprise an Intention-to-treat group, including all
patients with analysable data irrespective of fidelity,
compliance, or arm cross-over. Statisticians will finalise
a detailed Statistical Analysis Plan prior to the final T3
visit taking place and will remain blinded to study arm
until the analysis is complete.
A qualitative descriptive approach [48] will be taken to
the analysis of qualitative data. Braun and Clarke’s 6
stage approach to thematic analysis will be used to ana-
lyse all data collected [49]. A team of researchers will
analyse all transcripts following an agreed process using
nVivo 12 (QSR International, Australia).
Trial management and governance
Management of the ReStOre II study will be overseen by
three committees; a Trial management Group (TMG),
Trial Steering Committee (TSC) and an Independent
Data Monitoring Committee (IDMC). The TMG will
oversee the daily trial management. The TSC will meet
biannually and provide oversight of the trial and ensure
the trial is conducted in accordance with the principles
of Good Clinical Practice. The IDMC will monitor trial
data to ensure the safety of the participants. The IDMC
will meet biannually to review interim safety and accrual
data. In addition, the IDMC may also meet at the discre-
tion of the TSC.
Dissemination
Findings of ReStOre II will be disseminated via peer-
reviewed publications and conference presentations. Ag-
gregate study results will be presented to participants
and their families at an education symposium upon
study completion. Anonymised data and all computer
code used for the analyses will be made available on an
open access repository.
Public and patient involvement (PPI)
ReStOre II will involve a number of PPI initiatives.
Firstly, a previous ReStOre participant is a collaborator
on the trial and will sit on the TSC, and will review the
study protocol, study procedures and documentation.
Second, we have incorporated a PPI focused study
within a trial (SWAT) into this study [50–53]. The
SWAT will explore the effects of patient co-designed
participant information on study recruitment rates. The
protocol for the SWAT has been published separately
[54]. Third, past ReStOre participants will attend the
first class of each programme to meet and encourage
new participants. Finally, a patient representative will be
invited to speak at the education symposium.
Study status
ReStOre II will begin in summer 2020.
Discussion
The ReStOre II RCT, will investigate the efficacy of a
12-week multidisciplinary rehabilitation programme in
UGI and HPB cancer survivorship. Whilst the initially
feasibility of the programme is established in oesophago-
gastric cancer survivorship [21, 22], ReStOre II will now
examine the programme as a definitive intervention in a
wider cohort of UGI and HPB cancer survivors. The im-
portance and novel nature of this body of work cannot
be understated, particularly in view of the lack of evi-
dence supporting rehabilitative strategies in UGI and
HPB survivorship [2]. ReStOre II will be the first study
to examine by RCT the impact of multidisciplinary re-
habilitation following surgical resection for pancreatic or
hepatocellular carcinoma. ReStOre II will include a 1-
year follow-up evaluation of HRQOL, making it the first
RCT to examine the longer-term impact of rehabilitation
in UGI and HPB cancer survivorship. ReStOre II will
also be the first to examine the cost-effectiveness of re-
habilitation in UGI and HPB cancer survivorship. Fur-
thermore, ReStOre II will establish a national UGI and
HPB cancer survivorship biobank, allowing for innova-
tive investigation of the underpinning biological effects
of rehabilitation in the future.
A key strength of ReStOre II is the inclusion of cardio-
respiratory fitness as the primary outcome. Cardiorespi-
ratory fitness is a key predictor of health, cardiovascular
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and all-cause mortality, and HRQOL [55–57], and in-
creasingly is highlighted as a strong predictor of cancer
treatment outcomes [58], and survival [59, 60]. ReStOre
II is further strengthened by its mixed methods ap-
proach. A key finding of the ReStOre pilot RCT was that
there were many physical, mental, and social benefits to
participation in the ReStOre programme that were not
captured by HRQOL questionnaires, but captured in-
stead by the post-intervention focus groups [22, 23]. Re-
sultantly, ReStOre II will not only include post-
intervention focus groups, but will also incorporate a 1:1
interview at 3-months post-intervention, to explore the
longer-term effects of participation. This qualitative ap-
proach will provide substantial insight into the impact
and acceptability of rehabilitation in UGI and HPB can-
cer survivorship. Moreover, the ReStOre II programme
will also be enhanced by a greater focus on self-
management strategies, including personalised goal set-
ting. It is anticipated that this will aid participant’s sense
of autonomy over their rehabilitation, and therefore op-
timise long-term adherence to lifestyle changes. ReStOre
II will also benefit from the inclusion of PPI initiatives,
especially the guidance of the patient collaborator, keep-
ing the patient’s voice central to the ReStOre II study.
In conclusion, the ReStOre II RCT, will provide a
model of rehabilitation for survivors of UGI and HPB
cancer. This unique project addresses a clear gap in can-
cer research and will help inform much needed future
clinical rehabilitative services for UGI and HPB cancer
survivors.
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